Get the Stockscreener App
145.39
2.77%
-4.06
Charles River Laboratories International Inc stock is traded at $145.39, with a volume of 614.28K.
It is down -2.77% in the last 24 hours and down -11.40% over the past month.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
See More
Previous Close:
$149.45
Open:
$148.39
24h Volume:
614.28K
Relative Volume:
0.71
Market Cap:
$7.15B
Revenue:
$4.06B
Net Income/Loss:
$413.08M
P/E Ratio:
18.15
EPS:
8.01
Net Cash Flow:
$560.48M
1W Performance:
-7.44%
1M Performance:
-11.40%
6M Performance:
-9.94%
1Y Performance:
-24.67%
1-Day Range:
$144.26
$148.39
1-Week Range:
$144.26
$157.95
52-Week Range:
$91.86
$230.02
Charles River Laboratories International Inc Stock (CRL) Company Profile
Name
Charles River Laboratories International Inc
Sector
Industry
Phone
781-222-6000
Address
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
145.29 | 7.36B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
460.44 | 176.72B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
181.48 | 133.12B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
618.54 | 50.18B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
121.84 | 35.26B | 6.79B | 1.22B | 1.09B | 4.26 |
|
IQV
Iqvia Holdings Inc
|
176.71 | 30.81B | 15.70B | 1.24B | 2.01B | 6.91 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-25 | Upgrade | Jefferies | Hold → Buy |
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| May-23-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| May-14-25 | Upgrade | TD Cowen | Hold → Buy |
| May-08-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-21-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-04-25 | Upgrade | Citigroup | Sell → Neutral |
| Mar-03-25 | Upgrade | Redburn Atlantic | Sell → Neutral |
| Jan-22-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-17-25 | Downgrade | UBS | Buy → Neutral |
| Nov-18-24 | Downgrade | CLSA | Hold → Underperform |
| Nov-07-24 | Upgrade | CLSA | Underperform → Hold |
| Oct-23-24 | Initiated | CLSA | Underperform |
| Oct-14-24 | Initiated | Redburn Atlantic | Sell |
| Oct-07-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-01-24 | Downgrade | Citigroup | Neutral → Sell |
| Aug-08-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-08-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-24 | Downgrade | Argus | Buy → Hold |
| Jun-07-24 | Initiated | Mizuho | Neutral |
| Jun-06-24 | Initiated | Goldman | Buy |
| Feb-15-24 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-13-23 | Initiated | TD Cowen | Market Perform |
| Jul-10-23 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-12-23 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-04-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-24-22 | Initiated | Guggenheim | Neutral |
| Apr-25-22 | Downgrade | Jefferies | Buy → Hold |
| Apr-07-22 | Initiated | Stephens | Overweight |
| Feb-17-22 | Reiterated | BofA Securities | Buy |
| Feb-17-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-22 | Reiterated | Deutsche Bank | Buy |
| Feb-17-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-17-22 | Reiterated | UBS | Buy |
| Aug-05-21 | Resumed | Credit Suisse | Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-10-20 | Upgrade | Jefferies | Hold → Buy |
| Jul-01-20 | Upgrade | BofA Securities | Neutral → Buy |
| May-13-20 | Upgrade | UBS | Neutral → Buy |
| Apr-21-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-27-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Buy |
| Feb-18-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-10-20 | Upgrade | Goldman | Neutral → Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-18-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-10-19 | Initiated | SVB Leerink | Outperform |
| Apr-30-19 | Resumed | Evercore ISI | Outperform |
| Dec-14-18 | Initiated | Deutsche Bank | Buy |
| Oct-09-18 | Initiated | UBS | Neutral |
| Aug-23-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-17-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-15-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Feb-14-18 | Upgrade | SunTrust | Hold → Buy |
View All
Charles River Laboratories International Inc Stock (CRL) Latest News
Riverbridge Partners LLC Has $20.28 Million Stake in Charles River Laboratories International, Inc. $CRL - MarketBeat
Assenagon Asset Management S.A. Acquires 11,408 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
Pharmaceutical Contract Research Services Market Report 2025-2035: M&A, Partnerships, and Biologics Focus - GlobeNewswire Inc.
Is Charles River Laboratories Stock Underperforming The Nasdaq? - Barchart.com
Research Analysts Issue Forecasts for CRL Q3 Earnings - MarketBeat
Charles River Laboratories International (NYSE:CRL) Rating Lowered to "Buy" at Wall Street Zen - MarketBeat
Charles River Laboratories (CRL): Valuation Perspectives After CFO Transition, Guidance Reaffirmation, and New Oncology Partnerships - simplywall.st
Brokerages Set Charles River Laboratories International, Inc. (NYSE:CRL) Price Target at $177.07 - MarketBeat
Mice Model Market to Reach US$ 3.60 Bn by 2032, Expanding at 9.9% CAGRCoherent Market Insights | Charles River Laboratories, The Jackson Laboratory - industrytoday.co.uk
Charles River Laboratories International, Inc. $CRL Stock Position Lifted by Balefire LLC - MarketBeat
Fragasso Financial Advisors Inc Sells 2,140 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
How Charles River Laboratories’ CFO Transition and Maintained Outlook May Shift Its Investment Story (CRL) - simplywall.st
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Sells 51,622 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
Signal Recap: Will ERIE stock hit new highs in YEARQuarterly Portfolio Report & AI Enhanced Market Trend Forecasts - khodrobank.com
Sell Signal: Is Charles River Laboratories International Inc in accumulation or distribution phaseRecession Risk & Real-Time Volume Analysis - خودرو بانک
Argus Research Remains a Hold on Charles River Labs (CRL) - The Globe and Mail
Tech Rally: Will Charles River Laboratories International Inc. benefit from green energy policiesBuy Signal & Comprehensive Market Scan Reports - خودرو بانک
Market Recap: What are the future prospects of Charles River Laboratories International IncRate Cut & Precise Swing Trade Alerts - خودرو بانک
Volume Report: What are the future prospects of Charles River Laboratories International IncPortfolio Return Report & Precise Swing Trade Entry Alerts - خودرو بانک
Charles River Laboratories International (NYSE:CRL) Rating Increased to Strong-Buy at Wall Street Zen - MarketBeat
CEO Moves: Will Charles River Laboratories International Inc. outperform tech stocks2025 Fundamental Recap & Growth Focused Stock Reports - khodrobank.com
MBB Public Markets I LLC Purchases New Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
Here’s Why ClearBridge Investments Growth Strategy Closed Out Charles River Laboratories International (CRL) - Yahoo
Value Recap: What is Immuneering Corporation s debt to equity ratioJuly 2025 Patterns & Reliable Intraday Trade Alerts - khodrobank.com
Amundi Sells 53,919 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
Goldman Sachs Group Inc. Purchases 800,762 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
Institution Moves: Is Ovid Therapeutics Inc. a good ESG investment2025 Risk Factors & Fast Entry Momentum Trade Alerts - خودرو بانک
Charles River Laboratories Announces Chief Financial Officer Transition - BioSpace
Medical device maker Insulet taps industry veteran Flavia Pease as CFO - Reuters
Quarterly Trades: What is the long term forecast for Charles River Laboratories International Inc. stockWeekly Market Summary & Pattern Based Trade Signal System - خودرو بانک
Charles River Laboratories Appoints Michael G. Knell as Interim CFO - citybiz.co
Revenue Check: Will BLFS be affected by tariffsMarket Sentiment Review & Stepwise Trade Signal Implementation - خودرو بانک
Charles River Labs CFO takes job at local medical device giant - The Business Journals
Charles River Laboratories International, Inc. Announces Resignation of Flavia H. Pease, Corporate Executive Vice President from Her Role, Effective September 29, 2025 - MarketScreener
Charles River Laboratories International, Inc. Announces Chief Financial Officer Transition - MarketScreener
Charles River Laboratories (CRL) Appoints Interim CFO Amid Leade - GuruFocus
Charles River Laboratories (CRL) Maintains FY25 Revenue Forecast - GuruFocus
Charles River (CRL) Executive Moves to Insulet as CFO - GuruFocus
Jobs Data: Is Charles River Laboratories International Inc. in a long term uptrend2025 Stock Rankings & Precise Swing Trade Alerts - خودرو بانک
Charles River Laboratories International, Inc. Reaffirms Earnings Guidance for Year 2025 - MarketScreener
Logan Capital Management Inc. Has $1.74 Million Stake in Charles River Laboratories International, Inc. $CRL - MarketBeat
Aug Fed Impact: Whats next for Charles River Laboratories International Inc stock2025 Historical Comparison & Proven Capital Preservation Tips - خودرو بانک
Insider Sell: Is Charles River Laboratories International Inc. forming a breakout pattern2025 Biggest Moves & Community Shared Stock Ideas - خودرو بانک
Baird Adjusts PT on Charles River Laboratories International to $161 From $151, Maintains Neutral Rating - MarketScreener
Can Schneider National Inc scale operations efficiently2025 Stock Rankings & Advanced Swing Trade Entry Plans - خودرو بانک
Travel Stocks: Why is Charles River Laboratories International Inc. stock going upWeekly Earnings Recap & Real-Time Buy Signal Notifications - خودرو بانک
Charles River Laboratories International Inc Stock (CRL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):